Jesse J Hubbard
Overview
Explore the profile of Jesse J Hubbard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang S, Riccardi D, Pflanzer S, Redwine L, Gray H, Carson T, et al.
Nutrients
. 2023 Oct;
15(19).
PMID: 37836489
The practice of mindful eating brings awareness to food choices, brings attention to the eating experience, and encourages selecting and preparing food that is both satisfying and nourishing. We examined...
2.
Verdial F, Madtes D, Cheng G, Pipavath S, Kim R, Hubbard J, et al.
Chest
. 2019 Dec;
157(4):985-993.
PMID: 31862440
Background: Each year, > 1.5 million Americans are diagnosed with an incidentally detected lung nodule. Practice guidelines attempt to balance the benefit of early detection of lung cancer with the...
3.
Mark N, Kargl J, Busch S, Yang G, Metz H, Zhang H, et al.
Am J Respir Crit Care Med
. 2017 Sep;
197(3):325-336.
PMID: 28934595
Rationale: Chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC) are interrelated diseases with substantial mortality, and the pathogenesis of both involves aberrant immune functioning. Objectives: To profile...
4.
Amos P, Fung S, Case A, Kifelew J, Osnis L, Smith C, et al.
ASN Neuro
. 2017 Jul;
9(4):1759091417716610.
PMID: 28683563
Microglia are the primary innate immune cell type in the brain, and their dysfunction has been linked to a variety of central nervous system disorders. Human microglia are extraordinarily difficult...
5.
Kargl J, Busch S, Yang G, Kim K, Hanke M, Metz H, et al.
Nat Commun
. 2017 Feb;
8:14381.
PMID: 28146145
The response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%. To improve this figure, several early phase clinical trials combining novel immunotherapeutics with immune...
6.
Cheng G, Storer B, Chien J, Jagasia M, Hubbard J, Burns L, et al.
Ann Am Thorac Soc
. 2016 Aug;
13(11):1932-1939.
PMID: 27513368
Rationale: The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary...
7.
Hubbard J, Sullivan S, Mills J, Hayes B, Torok-Storb B, Ramakrishnan A
J Vis Exp
. 2014 Nov;
(92):e52009.
PMID: 25408260
This manuscript illustrates a protocol for efficiently creating integration-free human induced pluripotent stem cells (iPSCs) from peripheral blood using episomal plasmids and histone deacetylase (HDAC) inhibitors. The advantages of this...